Ocular Safety Profile of BRAF and MEK Inhibitors-Reference-Cited by-同舟云学术

Ocular Safety Profile of BRAF and MEK Inhibitors

Published:2021-12 Issue:12 Volume:128 Page:1748-1755
ISSN:0161-6420
Container-title:Ophthalmology
language:en
Short-container-title:Ophthalmology

Author:

Mettler Camille^ORCID,Monnet Dominique^ORCID,Kramkimel Nora,Tréluyer Jean-Marc,Mouthon Luc,Brézin Antoine,Dupin Nicolas^ORCID,Valnet-Rabier Marie-Blanche,Chouchana Laurent^ORCID,Terrier Benjamin

Funder

AbbVie

Allergan

AstraZeneca

Terumo BCT

Publisher

Elsevier BV

Subject

Ophthalmology

Reference33 articles.

1. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011

2. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial;Hauschild;Lancet,2012

3. Improved survival with MEK inhibition in BRAF-mutated melanoma;Flaherty;N Engl J Med,2012

4. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations;Flaherty;N Engl J Med,2012

5. The clinical development of MEK inhibitors;Zhao;Nat Rev Clin Oncol,2014

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐World Incidence of Incident Noninfectious Uveitis in Patients Treated With BRAF Inhibitors: A Nationwide Clinical Cohort Study;American Journal of Ophthalmology;2024-11

2. Reply;Ophthalmology;2024-07

3. Central retinal vein occlusion in patients with metastatic solid tumors on tyrosine kinase inhibitors: a report of case series and literature review;Frontiers in Medicine;2024-06-20

4. Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success;Current Oncology Reports;2024-06-08

5. VKH-like syndrome in the setting of Dabrafenib and Trametinib therapy for BRAF mutant metastatic melanoma: a case report;Journal of Surgical Case Reports;2024-03